Biotech Division of Greenland Mines Announces Issuance of Patent in Canada for the Klotho Gene Therapy Platform Technology for Alzheimer’s and Aging
Rhea-AI Summary
Greenland Mines (Nasdaq: GRML) announced that Innovation, Science and Economic Development Canada has granted Patent No. CA3,005,398 for a Klotho gene therapy platform licensed from researchers at Universitat Autònoma de Barcelona and collaborators.
The patent covers a nucleic acid sequence encoding secreted Klotho (s-KL), with 42 claims protecting synthesis, gene delivery methods and therapeutic use for multiple neurodegenerative and dementia-related conditions. According to Greenland Mines, KLTO-101, covered by this patent and others in the US, China and Europe, is scheduled to enter process development and manufacturing in August 2026, while KLTO-202 for ALS, multiple sclerosis and other neuromuscular disorders has advanced to GMP manufacturing and is expected to begin regulatory interactions before the end of 2026.
Positive
- Canadian patent CA3,005,398 granted with 42 claims covering s-KL gene therapy uses
- KLTO-101 to start process development and manufacturing in August 2026
- KLTO-202 advanced to GMP manufacturing; regulatory interactions planned before end of 2026
Negative
- None.
Market reaction after Canadian patent grant: GRML +3.97% in the Jul 28 session
In the Jul 28 session, GRML gained 3.97%, reflecting a moderate positive market reaction. Argus tracked a peak move of +9.3% during that session. Argus tracked a trough of -5.1% from its starting point during tracking. Our momentum scanner triggered 14 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 23 | Rights plan announcement | Neutral | -9.8% | Limited-duration rights plan adopted with a 15% triggering ownership threshold. |
| Jul 15 | Technical report update | Positive | +0.9% | Updated resource estimate reported higher contained PdEq ounces and grades. |
| Jul 10 | Australian patent grant | Positive | +1.2% | Australian patent grant expanded protection for Klotho neuromuscular therapy technology. |
| Jul 07 | Field campaign additions | Positive | -4.2% | Two specialists were added to support geological modeling and project evaluation. |
| Jun 25 | Technical workshop completion | Neutral | -8.0% | Workshop defined drilling, sampling, environmental, and engineering programs. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Comparable patent news produced a positive reaction, while several broader development announcements were followed by declines.
Key Terms
gene therapy medical
rna splice variant medical
epigenetic alterations medical
gmp manufacturing technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
CHARLOTTE, N.C., July 28, 2026 (GLOBE NEWSWIRE) -- via IBN -- Greenland Mines Ltd (Nasdaq: GRML) ("Greenland Mines" or the "Company") today announced that Innovation, Science and Economic Development Canada has granted Patent No. CA3,005,398, titled "SECRETED SPLICING VARIANT OF MAMMAL KLOTHO AS A MEDICAMENT FOR COGNITION AND MEMORY” covering technology exclusively licensed for worldwide commercialization from researchers at Universitat Autònoma de Barcelona and collaborating institutions. The issued patent protects the use of a human gene therapy using a nucleic acid gene sequence encoding the RNA splice variant protein called secreted Klotho or “s-KL”. The patent includes 42 granted claims of s-KL and its utility in treating several neurodegenerative diseases using a genetic-based therapy.
Because of epigenetic alterations that occur to DNA over a lifetime, the human Klotho gene gradually stops making the protein. The loss of the protein causes a cascade of events leading to diseases of aging. The Klotho-based therapies are being developed by the Company to bring the tissue concentrations of Klotho proteins back into the normal range of tissue concentrations found in normal healthy tissues. The objective is to prevent and/or treat diseases in tissues found in the brain, the heart, and other critical organs by returning those Klotho tissue levels to normal. Normal Klotho levels prevent many of the “Hallmarks of Aging” like telomer attrition, mitochondrial dysfunction, cell senescence, stem cell exhaustion and altered intercellular communication (altered transcription factor pathways). Klotho is often referred to as the “anti-aging gene”.
Dr. Joseph Sinkule, the Company’s founder and CEO, stated, "We continue to work with the Klotho gene and its two protein isoforms – secreted Klotho (s-KL) which is primarily produced in the human brain, and membrane-bound, soluble Klotho (m-KL) which is produced mainly in the kidneys. The patent in Canada further expands the Company's growing intellectual property platform supporting the Company’s Klotho-based therapeutic programs. The grant of 42 claims provides protection of the actual synthesis of the protein from the gene, the methods of delivery of the gene, and the utility of the RNA splice variant protein s-KL in the treatment of Alzheimer’s, Parkinson’s, Huntington’s, ALS, Dementia w Lewy bodies, Creutzfeldt-Jacob disease, Multiple Sclerosis, Ataxia telangiectasia, post-stroke Dementia, post-brain traumatic Dementia, Senile Dementia, and craniocerebral trauma. This is great news for us, now that we have issued patents for KLTO-101 in all major markets including the US, China and Europe”, stated Dr. Sinkule. The product candidate covered by the new patent granted in Canada and elsewhere, KLTO-101, will begin process development and manufacturing in August of 2026. As announced previously, the Company has advanced KLTO-202 for the treatment of ALS, multiple sclerosis and other neuromuscular disorders to the GMP manufacturing stage and will begin interaction with the FDA and other regulatory authorities before the end of 2026.
About Greenland Mines Ltd
Greenland Mines Ltd is a Nasdaq-listed company with two operating divisions: (1) Mining, focused on the exploration and development of the Skaergaard Project in southeast Greenland and, subject to closing of the previously announced transaction, the Sarfartoq neodymium-praseodymium (Nd-Pr) rare earths project in southwest Greenland; and (2) Biotech, including Klotho's KLTO‑202 primary indication for ALS. The Company’s strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals, and select midstream processing opportunities, while advancing its broader North Atlantic Critical Metals Corridor vision linking Greenland resources with allied downstream jurisdictions and industrial infrastructure.
Forward‑Looking Statements
This press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company's future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company's inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the "SEC") from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.
Investor Contact and Corporate Communications:
ir@greenlandmines.com
Website:
www.greenlandmines.com
